- Home
- RGC vs ARGX Comparison
RGC vs ARGX Comparison
Compare RGC & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- ARGX
- Stock Information
- Founded
- RGC 2014
- ARGX 2008
- Country
- RGC Hong Kong
- ARGX Netherlands
- Employees
- RGC N/A
- ARGX N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RGC Health Care
- ARGX Health Care
- Exchange
- RGC Nasdaq
- ARGX Nasdaq
- Market Cap
- RGC 38.6B
- ARGX 33.0B
- IPO Year
- RGC 2021
- ARGX 2017
- Fundamental
- Price
- RGC $13.70
- ARGX $555.96
- Analyst Decision
- RGC
- ARGX Strong Buy
- Analyst Count
- RGC 0
- ARGX 17
- Target Price
- RGC N/A
- ARGX $730.07
- AVG Volume (30 Days)
- RGC 2.8M
- ARGX 447.4K
- Earning Date
- RGC 06-30-2025
- ARGX 07-24-2025
- Dividend Yield
- RGC N/A
- ARGX N/A
- EPS Growth
- RGC N/A
- ARGX N/A
- EPS
- RGC N/A
- ARGX 15.94
- Revenue
- RGC N/A
- ARGX $2,643,062,000.00
- Revenue This Year
- RGC N/A
- ARGX $61.64
- Revenue Next Year
- RGC N/A
- ARGX $32.00
- P/E Ratio
- RGC N/A
- ARGX $32.12
- Revenue Growth
- RGC N/A
- ARGX 82.13
- 52 Week Low
- RGC $0.08
- ARGX $457.42
- 52 Week High
- RGC $83.60
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- RGC 44.61
- ARGX 48.18
- Support Level
- RGC $13.54
- ARGX $536.02
- Resistance Level
- RGC $30.00
- ARGX $571.99
- Average True Range (ATR)
- RGC 4.97
- ARGX 14.78
- MACD
- RGC -1.47
- ARGX 2.30
- Stochastic Oscillator
- RGC 20.91
- ARGX 74.12
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.